Home Featured Page 254

Featured

Latest

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files on Ibogaine & Magnesium

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul Austin

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at The Harvard Divinity School

UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in Parliamentary Report

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

DC’s Initiative 81 Becomes Law: Effectively Decriminalizes Entheogenic Plants and Fungi

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50%...

IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX...

Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its...

Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

Psychedelic Bulletin: Harvard Revisits Psychedelics; MindMed Attracts Strategic Investor; Psychedelics Companies...

Can Psilocybin Assisted Psychotherapy Change Attachment Style?

PTSF50 – Microdosing and the Placebo Effect, with Balázs Szigeti and...

Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment...

1...253254255...281 Page 254 of 281

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files...

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul...

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.